Revolutionizing
Diagnosis, Research, and Treatment of Depression
Pax Neuroscience has the potential to revolutionize depression management by accurately diagnosing patients and rapidly determining if a prescribed medication will be effective.
What We Do:
Pax's MoodMark® product platform can transform depression management and pharmaceutical research and development.
Depression Management
Patient diagnosis
Patient severity
Medication effectiveness
Learn More
Pharmaceutical R&D
Library screening
Clinical trial patient selection
Clinical trial endpoint measurement
Learn More
A World of Need
Depression affects 1 in 5 people in the United States and over 350 million people worldwide. It is the #1 cause of disability and #1 cause of suicide. While the prevalence of clinical depression rises, diagnosis continues to be based on subjective assessments, treatment determined largely by trial-and-error, and treatment evaluated with self-reported ratings that take weeks to indicate efficacy.
Leading With Science
Read about the discovery of MoodMark®, see the research behind the breakthrough, meet our distinguished Scientific Advisory Board, and keep up with our latest press and live media interviews.